MAIA Biotechnology, Inc.
Symbol: MAIA (NYSE)
1.66
0.00 0.000
Company Description:
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Key Stats
- Today's Open: $1.663
- Today's High: $1.663
- Today's Low: $1.66
- Today's Volume: 0
- Yesterday Close: $1.66
- Yesterday High: $1.69
- Yesterday Low: $1.59
- Yesterday Volume: 824.98K
- Last Min Volume: 0
- Last Min High: $1.663
- Last Min Low: $1.66
- Last Min VWAP: $0
Company Profile
- Name: MAIA Biotechnology, Inc.
- Website: https://www.maiabiotech.com
- Listed Date: 2022-07-28
- Location: CHICAGO, IL
- Market Status: Active
- CIK Number: 0001878313
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $54.77M
- Round Lot: 100
- Outstanding Shares: 32.99M
- Asset Type: CS
RECENT FILINGS FOR MAIA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-30 | 8-K | View |
| 2025-09-24 | 8-K | View |
| 2025-09-18 | 8-K | View |
| 2025-09-12 | 8-K | View |
| 2025-09-11 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-08-13 | 8-K | View |
| 2025-08-11 | 10-Q | View |
| 2025-07-28 | 8-K | View |
| 2025-07-17 | 8-K | View |
| 2025-07-09 | 8-K | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-07-02 | 4 | View |
| 2025-06-26 | 8-K | View |
| 2025-06-24 | 8-K | View |
| 2025-06-18 | 8-K | View |
Latest News on MAIA